PDS Biotechnology Corporation filed a Form 8-K on November 10, 2026, disclosing that NantWorks exercised outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of common stock at an exercise price of $0.22 per share, generating approximately $3.9 million in gross proceeds to the company.
Key Highlights
- Warrant holder: NantWorks exercised its outstanding common stock warrants, according to the filing.
- Shares covered: The warrants were exercised to purchase an aggregate of 17,699,115 shares of common stock, or pre-funded warrants in lieu thereof.
- Exercise price: The warrants were exercised at $0.22 per share.
- Gross proceeds: The company reported gross proceeds of approximately $3.9 million from the exercise.
- Announcement date: The press release was issued on November 10, 2026, as stated in the filing.
NantWorks Warrant Exercise Delivers $3.9 Million to PDS Biotechnology
PDS Biotechnology Corporation (NASDAQ:PDSB), a Delaware-incorporated clinical-stage company headquartered at 303A College Road East, Princeton, NJ 08540, filed an 8-K current report with the earliest event date of November 9, 2026. The filing was made under Item 8.01 (Other Events) and reports a development disclosed via press release on November 10, 2026.
According to the filing, NantWorks exercised its outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of the company's common stock, or pre-funded warrants in lieu thereof, at an exercise price of $0.22 per share. The company disclosed that gross proceeds from the exercise of these existing warrants were approximately $3.9 million. The filing does not specify how the proceeds will be used.
The 8-K was signed by Frank Bedu-Addo, Ph.D., President and Chief Executive Officer, on behalf of PDS Biotechnology Corporation. A copy of the press release dated November 10, 2026, was filed as Exhibit 99.1 and incorporated by reference into the report. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol PDSB with a par value of $0.00033 per share.
What Was Disclosed
PDS Biotechnology filed an 8-K reporting that NantWorks exercised warrants covering 17,699,115 shares of common stock at $0.22 per share, with gross proceeds to the company of approximately $3.9 million, as announced in a press release dated November 10, 2026.




Please wait processing your request...